BRAEBURN INC.

BRIXADI

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

BRAEBURN INC.

Brixadi HCPCS:

C9154

HCPCS Code Descriptor:

Injection, buprenorphine extended-release (brixadi), 1 mg

Category:

C Code

Brixadi NDCs:

No actively aligned NDCs found

Primary Type:

Opiod Abuse

Generic/Specialty Status:

Single-Source

Package Type:

Syringe

Route of Administration:

Subcutaneous

Brixadi CPT Codes:

-96372 - Therapeutic, prophylactic, and diagnostic injections and infusions (excludes chemotherapy and other highly complex drug or highly complex biologic agent administration)

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have not identified any potential errors with the NDCs mapped to this HCPCS code.

About Brixadi:

BRIXADI is an Opiod Abuse drug manufactured by Braeburn and administered via the subcutaneous route of administration. The C Code: C9154 is aligned to the drug BRIXADI.

ACCESS PRICING AND MORE BY REGISTERING

C9154 Added Date:

October 1, 2023

C9154 Effective Date:

October 1, 2023

C9154 Termination Date:

December 31, 2023

Brixadi billing and coding information can be found through Braeburn Inc. at the link below:
Brixadi patient assistance information can be found through Braeburn Pharmaceuticals at the URL: https://www.brixadi.com/
BRIXADI prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for BRIXADI. Please check back in a few weeks.